This is how exposed European Big Pharma is to the U.S.

European big pharma remains acutely exposed to the U.S. market, with a substantial portion of their revenues and, critically, their research and development budgets stemming from American sales. Companies like AstraZeneca, Sanofi, and Novartis consistently report that North America contributes a significant percentage to their top lines. This dominance offers lucrative opportunities due to higher drug prices and a robust healthcare infrastructure, but it also creates considerable vulnerability to evolving U.S. political and regulatory landscapes. The implications for investors are profound. Any proposed changes to U.S. drug pricing, such as those debated in Congress, or shifts in reimbursement policies by Medicare and private insurers, directly impact the profitability and future growth prospects of these European giants. The pursuit of blockbuster drugs tailored for the American market can also mean that pipeline failures have an outsized effect, given the concentrated investment in a single, albeit large, geographic region. This exposure necessitates a careful analysis of U.S. legislative actions and market trends when evaluating European pharmaceutical portfolios. Looking ahead, the ongoing debate around drug affordability and potential legislative reforms in the U.S. will be a critical determinant of European pharma's financial health. Investors should closely track H2 2024 congressional sessions and pharmaceutical lobbying efforts, as any policy changes could significantly reprice these companies' stocks. Diversification strategies by these firms into other global markets, while underway, are still insufficient to fully offset the U.S. market's prevailing influence.